Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mirum Pharmaceuticals Inc (MIRM)
NASDAQ:MIRM
RESEARCH TOOLSreports
Holding MIRM?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.3Last Year’s EPS
-$0.63Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -0.24%
|Next Earnings Date:Mar 05, 2025
Earnings Call Sentiment|Positive
The earnings call was largely positive with significant revenue growth, new product developments, and financial milestones like positive cash flow. However, the company reported a net loss and high operating expenses, which are areas of concern.Company Guidance
During the Mirum Pharmaceuticals Q3 2024 earnings call, the company reported robust financial and operational performance, with net product sales reaching $90.3 million, an 89% increase from the same quarter in 2023. This growth was driven by the strong performance of its three commercial medicines, notably LIVMARLI, which saw global sales rise to $59.1 million. The company revised its 2024 full-year revenue guidance upwards to $330 million to $335 million. Mirum highlighted significant pipeline advancements, including the FDA breakthrough designation for volixibat for cholestatic pruritus in PBC, based on the VANTAGE study's interim results. Additionally, the company is preparing for the December 28 PDUFA date for Chenodiol in CTX, and has enhanced its early-stage portfolio with MRM-3379 for Fragile X syndrome. The financial update revealed a positive operating cash flow for the first time, with operating expenses totaling $103.9 million, inclusive of R&D and SG&A costs. Mirum's strategic focus remains on leveraging its expertise in rare diseases to deliver high-impact therapies.Significant Revenue Growth
Third quarter 2024 net product sales reached $90.3 million, an 89% increase from the same quarter in 2023. Full-year guidance was raised to $330-$335 million.
Breakthrough Designation for Volixibat
Volixibat received breakthrough therapy designation for cholestatic pruritus in PBC based on the VANTAGE study interim results.
Priority Review for Chenodiol
The FDA granted priority review for the NDA in CTX with a PDUFA date of December 28, 2024.
Positive Operating Cash Flow
Achieved positive operating cash flow for the first time in Q3 2024.
Expansion into Fragile X Syndrome
Introduced MRM-3379, a candidate for Fragile X syndrome treatment, expanding the rare genetic neurology portfolio.
---
MIRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MIRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $41.61 | $42.28 | +1.61% |
| Aug 07, 2024 | $38.96 | $39.87 | +2.34% |
| May 08, 2024 | $25.04 | $25.83 | +3.15% |
| Feb 28, 2024 | $28.89 | $28.71 | -0.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Mirum Pharmaceuticals Inc (MIRM) report earnings?
Mirum Pharmaceuticals Inc (MIRM) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Mirum Pharmaceuticals Inc (MIRM) earnings time?
Mirum Pharmaceuticals Inc (MIRM) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MIRM EPS forecast?
MIRM EPS forecast for the fiscal quarter 2024 (Q4) is -$0.3.
---